Screening for atrial fibrillation in cancer: a randomised controlled clinical trial (SARIC)
Clicks: 1
ID: 323446
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #244 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Patients with cancer are at increased risk of atrial fibrillation (AF); however, to date, no randomised controlled trials have implemented and evaluated a systematic AF screening strategy in ambulatory patients with cancer, representing an important evidence gap in cardio-oncology. Purpose To implement and evaluate a single-timepoint AF screening strategy using a mobile electrocardiogram (ECG) device in ambulatory patients with cancer, and to assess its impact on AF detection, anticoagulation initiation, and AF prevalence. Methods We conducted an open-label, randomised controlled trial among ambulatory patients aged ≥65 years with a current or prior cancer diagnosis and no history of AF. Participants were randomised 1:1 to either a screening strategy consisting of a single 30-second handheld mobile ECG recording or to usual care without systematic screening. The primary outcome was newly diagnosed AF during follow-up. Secondary outcomes included initiation of oral anticoagulation following AF detection, and the prevalence of pre-existing AF among all eligible patients. Group comparisons were performed using Fisher’s exact test. Results Among 1,012 patients screened for eligibility, 480 were randomised (screening: n=242; usual care: n=238). The median age was 72 years (interquartile range 68.0–76.3), and 73.5% were female. During follow-up, AF was newly diagnosed in 5 patients (2.1%) in the screening group and 4 patients (1.7%) in the usual care group (p=1.00). Initiation of oral anticoagulation occurred in 1.7% of patients in both groups (p=1.00). Pre-existing AF was identified in 19% of the overall population. Conclusion In this first randomised clinical trial to implement and evaluate AF screening in ambulatory patients with cancer, a single-timepoint mobile ECG strategy was feasible but did not increase AF detection or anticoagulation initiation compared with usual care. Despite a high underlying prevalence of AF, brief single-timepoint screening was insufficient to identify new AF events, defining an important limitation of this approach in cardio-oncology. These findings provide prospective evidence to inform the design of future screening strategies, including longer-duration or repeated rhythm monitoring, tailored to ambulatory cancer populations.
| Reference Key |
openalex_W7172271350
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Z Asad, S Khan, W Razzaq, R Mannel, K Moore, S Koya, H Hatoum, T Al Juhaishi, M Toumpurleka, S Patel, L Dockery, R Al Jumaily, S George, S Ibrahimi, S Stavrakis |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.147
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.